Trial Watch: A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments
Important context
- Trial eligibility (participation has strict criteria): Clinical-trial participation has study-specific eligibility criteria; registry listing does not mean a person qualifies or should enroll.
In plain English
The 30-second version
What happened?
ClinicalTrials.gov confirms that this Phase 4 study is registered and currently listed as Not Yet Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
Why does it matter?
Phase 4 trials can contribute later-stage human evidence. CancerDiscoveries can track this record as results and regulatory information emerge.
What does this not prove?
A registered trial is not proof that the intervention works, is not FDA approval for this cancer or use, and is not a clinical-guideline recommendation.
Keep reading for evidence stage, limitations, study details, and sources.
What changed: ClinicalTrials.gov lists A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments (NCT07881835) as a Phase 4 interventional cancer study. The registry status is Not Yet Recruiting, with the record last updated 2026-10-19.
Study snapshot: Phase 4; Not Yet Recruiting; planned enrollment 75. Conditions listed: Relapsed/Refractory Multiple Myeloma, Multiple Myeloma. A primary outcome listed by the registry is: Adverse Events (AEs).
This entry tracks verified trial-registry facts. Trial registration by itself does not show that an intervention is effective, safe for a particular person, FDA-approved for this use, or recommended by clinical guidelines.
Population / Applicability
Studied in: Participants age 18 Years and older with Relapsed/Refractory Multiple Myeloma, Multiple Myeloma who meet the study-specific registry eligibility criteria. (Adults)
Eligibility is study-specific. Registry information does not determine whether any individual should enroll in or receive the intervention.
Full evidence details
- Study design
- Other / not applicable
- Sample size
- 75
- Primary outcome
- Adverse Events (AEs)
- Replication
- Unknown
Funding & Conflicts
ClinicalTrials.gov lists the lead sponsor as Pfizer. Sponsorship is reported for transparency and does not establish efficacy.
Regulatory status by jurisdiction
Unspecified jurisdiction
- Status
- Investigational
- Last verified
- 2026-10-20
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
Guideline positions
Guideline
- Position
- Not addressed
- Last verified
- 2026-10-20
Primary evidence supporting this story
- ClinicalTrials.gov — NCT07881835 (opens in a new tab) (Clinical-trial registry) NCT07881835 Load-bearing source NCT07881835
ClinicalTrials.gov — NCT07881835. NCT07881835.
Last reviewed
Trial Watch: A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments
https://cancerdiscoveries.com/discoveries/trial-watch-a-phase-iv-study-to-learn-about-the-study-medicine-called-elranatamab-in-people-with-multiple-myeloma-that-is-not-responding-to-four-or-more-standard-treatments-or-has-come-back-after-sev/
Evidence stage: Later-Stage Human
What This Means
ClinicalTrials.gov confirms that this Phase 4 study is registered and currently listed as Not Yet Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
What This Doesn't Mean
A registered trial is not proof that the intervention works, is not FDA approval for this cancer or use, and is not a clinical-guideline recommendation.
Why It Matters
Phase 4 trials can contribute later-stage human evidence. CancerDiscoveries can track this record as results and regulatory information emerge.
Important Limitations
- Clinical-trial participation has study-specific eligibility criteria; registry listing does not mean a person qualifies or should enroll.
Primary sources
- ClinicalTrials.gov — NCT07881835 — https://clinicaltrials.gov/study/NCT07881835 (NCT07881835)
Date verified: 2026-10-20
Correction status: No correction or retraction